Not exact matches
In its first test in humans, reported online October 4 in the New England Journal of Medicine, one
vaccine based on DNA from the virus elicited an immune response, with 100 percent of participants
developing antibodies after a three - dose
regimen.
Though these particular
vaccine regimens are not intended for the clinic, the results suggest that effective
vaccines for MERS could be
developed from the Spike protein, says study coauthor Barney Graham, a vaccinologist at the National Institute of Allergy and Infectious Diseases in Bethesda, Md..
• RV217 (ECHO): HIV - 1 Prevalence, Incidence, Cohort Retention, and Host Genetics and Viral Diversity in High Risk Cohorts in East Africa • Infectious Disease Surveillance (HIV, TB and Malaria) and Cohort Development Among Urban and Rural Communities • Karolinska Institute
vaccine study in Tanzania testing a prime - boost HIV
vaccine regimen using unadjuvanted DNA
vaccines followed by a Modified Vaccinia Ankara (MVA), which was
developed by MHRP and NIAID.